Richard David, MD
Urology · Sherman Oaks, CANPI 1427158245
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Astellas Pharma US Inc at 36.6% of the total. Reporting peaked in 2019 at $74,331 and has fallen 73.7% since, to $19,583 in 2025. Among urology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 844 payments — averaging $312.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$97K
- Accord Healthcare, Inc.$54K
- Butterfly Network, Inc.$35K
- Bayer$21K
- SN Holdings, LLC$15K
- Pfizer$7K
- plus $35K from 54 others
Across 51 payments — averaging $7814.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$205K
- Merck$71K
- Provepharm Inc.$59K
- Veru Inc.$45K
- Urogen Pharma, Inc.$18K
What the payments were for
- Consulting fees$67,17926%
- Speaking & faculty fees$135,74052%
- Travel & lodging$30,24211%
- Food & beverage$23,6399%
- Education$1850%
- Gifts$6,4342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$92,473
- CAMCEVI$53,648
- Butterfly iQ$34,707
- Nubeqa$15,194
- LYNPARZA$8,549
- Xofigo$5,978
- NOCDURNA$3,198
- JATENZO$1,125
- UroLift$926
- SEMI-RIGID URETEROSCOPES$400
- RIGID CYSTOSCOPES$400
- NEW PRODUCT DEVELOPMENT$400
- Erleada$285
- PROVENGE$258
- TRELSTAR$205
- XYOSTED$195
- UroLift System$142
- FIRMAGON$125
- AquaBeam Robotic System$118
- Nanoknife$101
How this compares
$263,418 in reported general payments places this provider in the 95th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 12 | $201,992 |
| GemtesaVibegron | 233 | $177,540 |
| OrgovyxRelugolix | 31 | $78,454 |
| MyrbetriqMirabegron | 57 | $47,830 |
| JatenzoTestosterone Undecanoate | 37 | $40,248 |
| Dutasteride | 224 | $11,199 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 203 | $5,859 |
| Potassium Citrate ErPotassium Citrate | 33 | $4,670 |
| Solifenacin Succinate | 80 | $4,518 |
| Estradiol | 57 | $3,719 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 30 | $3,430 |
| Tamsulosin Hcl | 217 | $2,969 |
| Testosterone | 30 | $2,872 |
| Finasteride | 124 | $2,685 |
| Methenamine Hippurate | 26 | $2,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $701 | $255,994264 claims |
| AstraZenecaLynparza | $5,729 | $201,99212 claims |
| Astellas Pharma US IncMyrbetriq | $96,503 | $47,83057 claims |
| Clarus Therapeutics Inc.Jatenzo | $444 | $40,24837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,324 urology providers in California.
Other urology in Sherman Oaks
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.